Enlivex reports durable 12-month Allocetra data in knee osteoarthritis trial
In patients 64 and older, 79.2% of Allocetra recipients showed a clinically meaningful response at 12 months versus 47.6% on placebo, Enlivex said.
SEC filing (2)
Latest
Monday, November 2
HUTCHMED's Orpathys-Tagrisso filings for lung cancer accepted in Europe and Japan
The regulatory filings follow an FDA submission in September 2026 and build on SAFFRON Phase III data showing a 45% cut in progression risk and nearly five months of added survival.
SEC filing (3)
Friday, October 30
Acumen's sabirnetug fails Phase 2 Alzheimer's trial, company halts development
ALTITUDE-AD missed its primary cognitive endpoint at both doses, and Acumen will stop development of sabirnetug while weighing strategic options.
SEC filing
Rapport closes $215.7 million stock offering and $172.5 million convertible notes sale
Both offerings closed October 30, 2026, with underwriters fully exercising options on shares and notes, as Rapport advances RAP-219 toward Phase 3 trials in epilepsy and bipolar mania.
SEC filing (8)
VistaGen cuts workforce by about 31%, citing focus on Phase 3 fasedienol work
The company said the move preserves staff needed for registration-directed Phase 3 trials of fasedienol while trimming costs.
SEC filing
Vor Biopharma launches up to $150 million at-the-market stock offering
Vor filed a prospectus supplement on October 30, 2026 to sell shares through William Blair and RBC Capital Markets after its prior $125 million Stifel agreement expired.
SEC filing
Rhythm Pharmaceuticals posts Phase 2 results for bivamelagon in hypothalamic obesity
Zeo ScientifiX and Pluri sign license-for-equity deal, Pluri to own 50%
Pluri will license its 3D cell-expansion manufacturing technology to Zeo and take majority voting control through new preferred stock, with closing targeted for the fourth quarter of 2026.
SEC filing
Aurinia starts PRESERVE trial combining LUPKYNIS with biologics in lupus nephritis
The company raised 2026 revenue guidance and reported a new Phase 4 study pairing LUPKYNIS with belimumab, obinutuzumab or anifrolumab.
SEC filing
Aptevo discloses $2.3 million current ATM offering capacity as of Oct 30, 2026
New prospectus supplement sets Aptevo's allowable stock sales under its Roth Capital Partners at-the-market agreement based on updated public float.
SEC filing
Arrowhead's ARO-INHBE obesity trial remains active, not recruiting, with 190 enrolled
Biogen posts Phase 4 RESPOND results for nusinersen after onasemnogene abeparvovec
Merck registers new MK-8644 psoriasis trial; RA and HIV/HPV vaccine trials continue
Pluri signs ZEO license deal, raises $1 million, and EIB sells loan to chairman's entity
Pluri Inc. entered a Partnership Agreement with ZEO ScientifiX, Inc. on October 26, 2026.
SEC filing
Annovis Bio gets NYSE notice for falling below market cap and equity thresholds
Annovis Bio said the NYSE flagged it for noncompliance with listing standards after its market cap and stockholders' equity both fell below $50 million.
SEC filing
Boehringer posts Phase III AIRWARD COPD trial for verducatib; also lists Phase I BI 3821001 study
Omeros grants CEO performance stock option tied to share-price hurdles
The board's compensation committee awarded Gregory Demopulos an option for up to 500,000 shares that vests only if Omeros stock hits price targets from $25 to $40.
SEC filing
Organon suspends earnings call as Sun Pharma merger proceeds, reports Q3 results
Organon filed its third-quarter 2026 10-Q and furnished supplemental non-GAAP data instead of holding its usual earnings release and call, citing the pending Sun Pharma merger.
SEC filing
Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosis
Roche group registers Phase III UC trial, GA-AMD study; AD extension stays active
Actuate Therapeutics gets Nasdaq notice for failing minimum bid price rule
Actuate has until April 26, 2027 to lift its stock price back above $1.00 or face possible delisting from the Nasdaq Global Market.
SEC filing
Novartis posts Cosentyx nail psoriasis and imatinib results; Piqray label updated
Allarity Therapeutics ends equity line of credit with Tumim Stone Capital
Allarity terminated its common stock purchase agreement with Tumim effective October 28, 2026, closing out the primary stock offering tied to the facility.
SEC filing
GSK's Benlysta label updated by FDA; Phase 2a NASH trial posts results
AstraZeneca's FORTUNA misses in NASH as ARTEMIS kidney trial ends for lack of efficacy
Lilly-linked brain metastases trial posts results; two baricitinib studies complete
Amneal secures three mometasone furoate labeling supplement approvals in one week
Janssen registers Phase 3 TRIlogy-6 trial in newly diagnosed multiple myeloma
Allarity Therapeutics ends $6 million stock purchase deal with Tumim Stone Capital
Allarity terminated its equity line agreement with Tumim effective October 28, 2026, as it looks at other ways to raise money.
SEC filing
Alterity confirms FDA-aligned Phase 3 design for ATH434 in MSA, reports A$41.3M cash
The company said FDA End-of-Phase 2 minutes confirmed the Phase 3 pathway for ATH434 as it reported quarterly results for the period ended September 30, 2026.
SEC filing
Tempest Therapeutics names Stephanie Horn-Warnock as CFO after Constance Ames resigns
The Brisbane biotech disclosed a same-day CFO transition effective October 26, 2026, with the incoming finance chief working under a consulting engagement at $450 per hour.
SEC filing
GridAI amends interim CFO's consulting pay and RSU terms
GridAI Technologies amended its agreement with interim CFO Anna Skowron's consulting firm, setting a flat $27,000 monthly retainer and new RSU vesting terms, effective September 1, 2026.
SEC filing (2)
Vertex Phase 1 study compares VX-581 tablet and suspension formulations in healthy adults
Neumora Therapeutics gets Nasdaq notice for falling below $1.00 bid price minimum
Neumora has until April 26, 2027 to bring its stock price back above $1.00 for ten straight business days or face possible delisting.
SEC filing
UIC registers Phase 1 trial of Pfizer's elranatamab in plasmablastic lymphoma
Harmony Biosciences details CEO transition pay in amended 8-K filing
The company filed terms of Jeffrey Dayno's separation and Peter Anastasiou's new employment agreement tied to the CEO succession announced October 12, 2026.
SEC filing
Change Agents stockholders approve 17 proposals at special meeting
Shareholders cleared equity issuances, a charter amendment, and a stock plan expansion tied to Nasdaq compliance and existing financing agreements.
SEC filing
Pelthos Therapeutics to merge with Castle Creek Biosciences in stock-and-milestone deal
The combined company would pair Pelthos' dermatology products with Castle Creek's gene therapy candidate D-Fi for a rare skin disease, with closing targeted by the end of the first quarter of 2027.
SEC filing
NextCure chief medical officer to depart ahead of Avere Therapeutics merger
Dr. Udayan Guha's exit, effective October 31, 2026, comes as NextCure's merger with Avere Therapeutics remains pending.
SEC filing
Edgewise-linked Becker muscular dystrophy natural history study marked completed, update posted
Sanofi registers three-country OPTIMUS RISK cardiovascular cohort studies in ASCVD patients
Thursday, October 29
FDA approves efficacy supplement for Sun Pharma's Ilumya
The FDA cleared a supplemental Biologics License Application for tildrakizumab-asmn, classified as an efficacy submission, with a status date of October 29, 2026.
Drugs@FDA
Estrella Immunopharma names Cynthia Pussinen CEO and board chair
Cheng Liu moves from CEO to Chief Scientific Officer while remaining President and a director, the company said in an October 29, 2026 filing.
SEC filing
Incyte reports GVHD cream results; INCA033989 Phase 1 PK study stays active
ProKidney sets up $200 million at-the-market stock sale facility with Jefferies
ProKidney entered an Open Market Sale Agreement with Jefferies on October 29, 2026, allowing it to sell up to $200 million in Class A shares over time.
SEC filing
Bausch posts Phase 3 rifaximin cirrhosis results; pediatric plecanatide trial record updated
Jade Biosciences registers Phase 3 trial of JADE101 in IgA nephropathy
Teva Pharmaceutical adds David Brailer to board of directors
Teva's board elected Dr. David J. Brailer as a new independent director effective November 3, 2026, following an October 27 board meeting.
SEC filing
Innovent registers Phase 1 trial of IBI3043 in advanced solid tumors
GlucoTrack to be delisted from Nasdaq after missing bid price deadline
Nasdaq will suspend trading in GlucoTrack's common stock on October 30, 2026, after the company failed to maintain a $1.00 closing bid price through its compliance deadline.
SEC filing